Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Sodium chloride; Magnesium chloride hexahydrate; Potassium chloride; Sodium gluconate; Sodium acetate trihydrate
Baxter Healthcare Limited
B05BB; B05BB01
Sodium chloride; Magnesium chloride hexahydrate; Potassium chloride; Sodium gluconate; Sodium acetate trihydrate
Unknown
Solution for infusion
Product subject to prescription which may not be renewed (A)
Solutions affecting the electrolyte balance; electrolytes
Authorised
2017-07-07
Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. This medicine is called `Plasma-Lyte 148 (pH 7.4) Solution for Infusion’, but will be referred to as `Plasma-Lyte 148 (pH 7.4) infusion’ throughout the remainder of this leaflet. What is in this leaflet: 1. What Plasma-Lyte 148 (pH 7.4) Infusion is and what it is used for 2. What you need to know before you use Plasma-Lyte 148 (pH 7.4) Infusion 3. How to use Plasma-Lyte 148 (pH 7.4) Infusion 4. Possible side effects 5. How to store Plasma-Lyte 148 (pH 7.4) Infusion 6. Contents of the pack and other information 1. What Plasma-Lyte 148 (pH 7.4) Infusion is and what it is used for Pharmacotherapeutic group: “Electrolytes” - ATC code: “B05BB01” Plasma-Lyte 148 (pH 7.4) Infusion is a solution of the following substances in water: • sodium chloride • potassium chloride • magnesium chloride hexahydrate • sodium acetate trihydrate • sodium gluconate Sodium, potassium, magnesium, chloride, acetate and gluconate are chemical substances found in the blood. Plasma-Lyte 148 (pH 7.4) infusion is used: • to provide a source of fluid, for example in cases of: – burns – head injury – fractures – infection – peritoneal irritation (inflammations within the abdomen) • as a source of fluids during a surgical operation • for the treatment of shock due to loss of blood and for other conditions needing rapid replacement of blood and/or fluids • in metabolic acidosis (when the blood becomes too acid) that is not life-threatening • lactic acidosis (a type of metabolic acidosis caused by the accumulation of lactic acid in the body). Lactic acid is produced mainly by the muscles and is removed by the liver. Plasma-Lyte 148 (pH 7.4) i Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Plasma-Lyte ® 148 (pH 7.4) solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sodium Chloride:............................................................................................. 5.26 g/l Potassium Chloride:.......................................................................................... 0.37 g/l Magnesium Chloride hexahydrate:................................................................... 0.30 g/l Sodium Acetate trihydrate:............................................................................... 3.68 g/l Sodium Gluconate:........................................................................................... 5.02 g/l Na + K + Mg ++ Cl - CH 3 COO - C 6 H 11 O 7 - (Acetate) (Gluconate) mmol/l 140 5.0 1.5 98 27 23 mEq/l 140 5.0 3.0 98 27 23 For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for infusion. Clear solution, free from visible particles Osmolarity: 295 mOsm/l (approx.) pH: approx. 7.4 (6.5 to 8.0) 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Plasma-Lyte 148 (pH 7.4) is indicated: - for fluid replacement (e.g. after burns, head injury, fracture, infection, and peritoneal irritation), - as intraoperative fluid replacement, - in haemorrhagic shock and clinical conditions requiring rapid blood transfusions (compatibility with blood), - in mild to moderate metabolic acidosis, also in case of lactate metabolism impairment. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology: _ADULTS, OLDER PATIENTS AND ADOLESCENTS (AGE 12 YEARS AND OVER):_ The dosage and rate of administration depend on the age, weight, clinical and biological conditions of the patient and concomitant therapy. The recommended dosage is: 500 ml to 3 litres / 24 h _Administration rate:_ The infusion rate is usually 40 mL/kg/24h in adults, the elderly and adolescents. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _ Read the complete document